Bladder cancer
Conditions
Interventions
On the day before surgery (approximately 18 hours) patients will receive 4-6 transurethral injections with a total of 2mL hybrid tracer (240MBq) around the tumor (in case of a solitary lesion) or divi
Sponsors
The Netherlands Cancer Institute - Antoni van Leeuwenhoek Hospital, Plesmanlaan 121, 1066 CX, Amsterdam, the Netherlands
Eligibility
Inclusion criteria
Inclusion criteria: - Patients >18 years; - Histopathologically proven bladder cancer; - Patients are cN0M0; - Patients scheduled for radical cystectomy with or without neo-adjuvant chemotherapy.
Exclusion criteria
Exclusion criteria: - Preoperatively known distant metastases (M1); - Clinically tumor-positive nodes; - Patients scheduled for brachytherapy of the bladder; - Previous radiation therapy of the pelvis; - Previous pelvic surgery for other reasons such as urologic and gynecologic malignancies (exception: trans-urethral operations like e.g. transurethral bladder resection).
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Evaluate the accuracy of the sentinel node biopsy procedure for nodal staging in patients with non-metastatic (cN0M0) muscle-invasive bladder cancer. | — |
Secondary
| Measure | Time frame |
|---|---|
| 1. Evaluation of the feasibility of sentinel node mapping in bladder cancer patients using the hybrid tracer (ICG-99mTc-nanocolloid); 2. Evaluation of intraoperative fluorescence detection of the SNs via fluorescence imaging; 3. Evaluation of the feasibility of sentinel node localization via intraoperative (SPECT/CT-based and freehandSPECT). | — |
Contacts
Public ContactBas van Rijn
Plesmanlaan 121
Outcome results
None listed